Your browser doesn't support javascript.
loading
Emotional processing intervention (EMOPRINT): A blinded randomized control trial to treat facial affect recognition deficits in multiple sclerosis.
Genova, Helen M; Lancaster, Katie; Myszko, Zuzanna; Morecraft, Jimmy; Leddy, Jacqueline; Smith, Angela; Chiaravalloti, Nancy; Lengenfelder, Jean.
Afiliação
  • Genova HM; Kessler Foundation, 120 Eagle Rock Ave, Suite 100, East Hanover, New Jersey, USA; Rutgers New Jersey Medical School, 90 Bergen Street, Suite 3100, Newark, New Jersey, USA. Electronic address: hgenova@kesslerfoundation.org.
  • Lancaster K; Kessler Foundation, 120 Eagle Rock Ave, Suite 100, East Hanover, New Jersey, USA; Rutgers New Jersey Medical School, 90 Bergen Street, Suite 3100, Newark, New Jersey, USA.
  • Myszko Z; Kessler Foundation, 120 Eagle Rock Ave, Suite 100, East Hanover, New Jersey, USA.
  • Morecraft J; Bristol Myers Squibb, 80 Morris Avenue, Summit, New Jersey, USA.
  • Leddy J; Kessler Foundation, 120 Eagle Rock Ave, Suite 100, East Hanover, New Jersey, USA.
  • Smith A; Kessler Foundation, 120 Eagle Rock Ave, Suite 100, East Hanover, New Jersey, USA.
  • Chiaravalloti N; Kessler Foundation, 120 Eagle Rock Ave, Suite 100, East Hanover, New Jersey, USA; Rutgers New Jersey Medical School, 90 Bergen Street, Suite 3100, Newark, New Jersey, USA.
  • Lengenfelder J; Kessler Foundation, 120 Eagle Rock Ave, Suite 100, East Hanover, New Jersey, USA; Rutgers New Jersey Medical School, 90 Bergen Street, Suite 3100, Newark, New Jersey, USA.
Mult Scler Relat Disord ; 59: 103536, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35093842
OBJECTIVE: Facial affect recognition deficits have been noted in persons with MS, however there is no treatment for these impairments. We investigated the efficacy of the Emotional Processing Intervention (EMOPRINT), a 12-session behavioral intervention teaching facial affect recognition skills and mimicry to improve facial affect recognition abilities in persons with MS. METHODS: This double blind, placebo-controlled, randomized clinical trial with two time points (pre-treatment; post-treatment) included 36 participants with clinically definite MS, 21 in the treatment group and 15 in the placebo control group. Participants completed a pre-test and post-test neuropsychological assessment, which consisted of tasks of facial affect recognition (primary outcome measure) and questionnaires to assess quality of life and emotional functioning (secondary outcome measures). We hypothesized that improvements in facial affect recognition skills would be observed following treatment. We also examined changes to quality of life and social functioning. Changes in outcome measures were analyzed using a mixed-method analysis of variance. RESULTS: The treatment group showed significantly improved facial affect recognition skills relative to the placebo group post-treatment, F(1,34)=5.91, p=.022, partial ꞃ2=0.146. No significant change was noted on secondary outcomes. The majority of the participants in the intervention group reported that the intervention was helpful and that they used the skills learned in their daily interactions. CONCLUSION: EMOPRINT is effective for improving facial affect recognition skills in MS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Tipo de estudo: Clinical_trials Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Mult Scler Relat Disord Ano de publicação: 2022 Tipo de documento: Article País de publicação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Tipo de estudo: Clinical_trials Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Mult Scler Relat Disord Ano de publicação: 2022 Tipo de documento: Article País de publicação: Holanda